Document Type
Article
Publication Date
9-12-2017
Abstract
Objective: To evaluate patient perspectives regarding utilization of intravenous (IV) therapy for inflammatory arthritis (IA). Methods: This was a single-center, non-interventional, patient questionnaire-based study of adult IA patients currently receiving IV biologics. At a single visit, patients completed the questionnaire comprising 30 questions centered on their experience receiving an intravenously administered therapy to treat their IA. The questionnaire included questions on patient demographics, disease characteristics, and previous biologic treatment for IA (subcutaneous [SC] and IV). Patients rated their level of agreement with statements regarding satisfaction with current IV biologic therapy and potential advantages and disadvantages of IV biologic therapy using a 5-point Likert scale (1= strongly disagree, 5= strongly agree). Results: One hundred patients were enrolled and completed the survey; 66% were female and the mean age was 58 years. Before IV treatment, 97% of patients received information regarding therapy options. Ninety patients ranked their satisfaction with current IV therapy as 4 or 5. The proportion of patients with an “extremely favorable” perception of IV therapy increased from 33% to 71% following initiation of their current medication. Thirty-one patients had previously received SC therapies to treat their IA. Conclusion: These results demonstrated an overall favorable perception of IV therapy among this patient population. Patients previously treated with SC therapy also had a positive shift in the perception of IV therapy after initiating IV therapy. Patients’ perception and preference for treatment options should be highly considered by the treating physician during or as part of a shared decision-making process. © 2017 Gaylis et al.
Recommended Citation
Gaylis, Norman B.; Sagliani, Joanne; Black, Shawn; Tang, Kezhen L.; DeHoratius, Raphael J.; Kafka, Wesley A.; and Parenti, Dennis, "Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy" (2017). Department of Medicine Faculty Papers. Paper 215.
https://jdc.jefferson.edu/medfp/215
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License
Comments
This article has been peer reviewed. It is the author’s final published version in Patient Preference and Adherence
Volume 11, September 2017, Pages 1543-1553.
The published version is available at DOI: 10.2147/PPA.S136567. Copyright © Gaylis et al.
Published by Dove Medical Press